This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non–muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.

  • 1.

    SiegelRLMillerKDJemalA. Cancer statistics, 2017. CA Cancer J Clin2017;67:730.

  • 2.

    Cancer Stat Facts: Bladder Cancer. Available at: https://seer.cancer.gov/statfacts/html/urinb.html. Accessed July 25 2017.

  • 3.

    MochHHumphreyPAUlbrightTMReuterVE. Tumours of the Urinary Tract. In: WHO Classification of Tumours of the Urinary System and Male Genital Organs4th ed.Lyon, France: IARC; 2016.

    • Search Google Scholar
    • Export Citation
  • 4.

    HumphreyPAMochHCubillaAL. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol2016;70:106119.

    • Search Google Scholar
    • Export Citation
  • 5.

    AthanazioDATrpkovK. What is new in genitourinary pathology? Recent developments and highlights of the new 2016 World Health Organization classification of tumors of the urinary system and male genital organs. Applied Cancer Research2016;36:1.

    • Search Google Scholar
    • Export Citation
  • 6.

    ChalasaniVChinJLIzawaJI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J2009;3:S193198.

    • Search Google Scholar
    • Export Citation
  • 7.

    Siefker-RadtkeA. Urachal adenocarcinoma: a clinician's guide for treatment. Semin Oncol2012;39:619-624.

  • 8.

    VermaSRajeshAPrasadSR. Urinary bladder cancer: role of MR imaging. Radiographics2012;32:371387.

  • 9.

    SolsonaEIborraIColladoA. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol2010;184:475480.

    • Search Google Scholar
    • Export Citation
  • 10.

    LeiboviciDKassoufWPistersLL. Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology2007;70:473476.

    • Search Google Scholar
    • Export Citation
  • 11.

    ShariatSFPalapattuGSKarakiewiczPI. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol2007;51:137149; discussion 149–151.

    • Search Google Scholar
    • Export Citation
  • 12.

    LeissnerJHohenfellnerRThuroffJWWolfHK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int2000;85:817823.

    • Search Google Scholar
    • Export Citation
  • 13.

    HerrHWBochnerBHDalbagniG. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol2002;167:12951298.

    • Search Google Scholar
    • Export Citation
  • 14.

    HerrHWFaulknerJRGrossmanHB. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol2004;22:27812789.

    • Search Google Scholar
    • Export Citation
  • 15.

    KonetyBRJoslynSAO'DonnellMA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol2003;169:946950.

    • Search Google Scholar
    • Export Citation
  • 16.

    WrightJLLinDWPorterMP. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer2008;112:24012408.

    • Search Google Scholar
    • Export Citation
  • 17.

    GrossmanHBNataleRBTangenCM. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med2003;349:859866.

    • Search Google Scholar
    • Export Citation
  • 18.

    SherifAHolmbergLRintalaE. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol2004;45:297303.

    • Search Google Scholar
    • Export Citation
  • 19.

    WinquistEKirchnerTSSegalR. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol2004;171:561569.

    • Search Google Scholar
    • Export Citation
  • 20.

    VashisthaVQuinnDIDorffTBDaneshmandS. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer2014;14:966.

    • Search Google Scholar
    • Export Citation
  • 21.

    Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol2005;48:202205; discussion 205–206.

    • Search Google Scholar
    • Export Citation
  • 22.

    GriffithsGHallRSylvesterR. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol2011;29:21712177.

    • Search Google Scholar
    • Export Citation
  • 23.

    SternbergCNde MulderPSchornagelJH. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer2006;42:5054.

    • Search Google Scholar
    • Export Citation
  • 24.

    PlimackERHoffman-CensitsJHViterboR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol2014;32:18951901.

    • Search Google Scholar
    • Export Citation
  • 25.

    ChoueiriTKJacobusSBellmuntJ. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol2014;32:18891894.

    • Search Google Scholar
    • Export Citation
  • 26.

    McConkeyDJChoiWShenY. A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol2016;69:855862.

    • Search Google Scholar
    • Export Citation
  • 27.

    MillikanRDinneyCSwansonD. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol2001;19:40054013.

    • Search Google Scholar
    • Export Citation
  • 28.

    GalskyMDStenslandKDMoshierE. Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J Clin Oncol2016;34:825832.

    • Search Google Scholar
    • Export Citation
  • 29.

    LeowJJMartin-DoyleWRajagopalPS. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol2014;66:4254.

    • Search Google Scholar
    • Export Citation
  • 30.

    HussainMHWoodDPBajorinDF. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol2009;27:56805684.

  • 31.

    LehmannJFranzaringLThuroffJ. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int2006;97:4247.

    • Search Google Scholar
    • Export Citation
  • 32.

    StockleMWellekSMeyenburgW. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology1996;48:868875.

    • Search Google Scholar
    • Export Citation
  • 33.

    SkinnerDGDanielsJRRussellCA. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol1991;145:459464; discussion 464–457.

    • Search Google Scholar
    • Export Citation
  • 34.

    Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol2005;48:189199; discussion 199–201.

    • Search Google Scholar
    • Export Citation
  • 35.

    SternbergCNde MulderPHSchornagelJH. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol2001;19:26382646.

    • Search Google Scholar
    • Export Citation
  • 36.

    DashAPettusJA4thHerrHW. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer2008;113:24712477.

    • Search Google Scholar
    • Export Citation
  • 37.

    von der MaaseHHansenSWRobertsJT. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol2000;18:30683077.

    • Search Google Scholar
    • Export Citation
  • 38.

    NovotnyVFroehnerMMayM. Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder. World J Urol2015;33:17531761.

    • Search Google Scholar
    • Export Citation
  • 39.

    KuJHKimMJeongCW. Risk prediction models of locoregional failure after radical cystectomy for urothelial carcinoma: external validation in a cohort of korean patients. Int J Radiat Oncol Biol Phys2014;89:10321037.

    • Search Google Scholar
    • Export Citation
  • 40.

    ChristodouleasJPBaumannBCHeJ. Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer2014;120:12721280.

    • Search Google Scholar
    • Export Citation
  • 41.

    ZaghloulMSAwwadHKAkoushHH. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys1992;23:511517.

    • Search Google Scholar
    • Export Citation
  • 42.

    ZaghloulMSChristodouleasJPSmithA. Adjuvant sandwich chemotherapy and radiation versus adjuvant chemotherapy alone for locally advanced bladder cancer [abstract]. Int J Radiat Oncol Biol Phys2016;96:Abstract S94.

    • Search Google Scholar
    • Export Citation
  • 43.

    GakisGEfstathiouJLernerSP. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol2013;63:4557.

    • Search Google Scholar
    • Export Citation
  • 44.

    Bladder cancer: diagnosis and management. National Institute for Health and Care Excellence Web site. Available at: https://www.nice.org.uk/guidance/ng2. Accessed August 7 2017.

    • Search Google Scholar
    • Export Citation
  • 45.

    ChangSSBochnerBHChouR. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol2017;198:552559.

    • Search Google Scholar
    • Export Citation
  • 46.

    FedeliUFedewaSAWardEM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol2011;185:7278.

    • Search Google Scholar
    • Export Citation
  • 47.

    GrayPJFedewaSAShipleyWU. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol2013;63:823829.

    • Search Google Scholar
    • Export Citation
  • 48.

    HerrHWBajorinDFScherHI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol1998;16:12981301.

    • Search Google Scholar
    • Export Citation
  • 49.

    SplinterTDenisL. Restaging procedures, criteria of response, and relationship between pathological response and survival. Semin Oncol1990;17:606612.

    • Search Google Scholar
    • Export Citation
  • 50.

    HoussetMMaulardCChretienY. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol1993;11:21502157.

    • Search Google Scholar
    • Export Citation
  • 51.

    ShipleyWUKaufmanDSZehrE. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology2002;60:6267; discussion 67–68.

    • Search Google Scholar
    • Export Citation
  • 52.

    ShipleyWUWinterKAKaufmanDS. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol1998;16:35763583.

    • Search Google Scholar
    • Export Citation
  • 53.

    RodelCGrabenbauerGGKuhnR. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol2002;20:30613071.

    • Search Google Scholar
    • Export Citation
  • 54.

    EfstathiouJASpiegelDYShipleyWU. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol2012;61:705711.

    • Search Google Scholar
    • Export Citation
  • 55.

    GiacaloneNJShipleyWUClaymanRH. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol2017;71:952960.

    • Search Google Scholar
    • Export Citation
  • 56.

    ZapateroAMartin De VidalesCArellanoR. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy. Urology2012;80:10561062.

    • Search Google Scholar
    • Export Citation
  • 57.

    KaufmanDSWinterKAShipleyWU. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist2000;5:471476.

    • Search Google Scholar
    • Export Citation
  • 58.

    HaganMPWinterKAKaufmanDS. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys2003;57:665672.

    • Search Google Scholar
    • Export Citation
  • 59.

    KaufmanDSWinterKAShipleyWU. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology2009;73:833837.

    • Search Google Scholar
    • Export Citation
  • 60.

    MitinTHuntDShipleyWU. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol2013;14:863872.

    • Search Google Scholar
    • Export Citation
  • 61.

    EfstathiouJABaeKShipleyWU. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol2009;27:40554061.

    • Search Google Scholar
    • Export Citation
  • 62.

    CoppinCMGospodarowiczMKJamesK. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol1996;14:29012907.

    • Search Google Scholar
    • Export Citation
  • 63.

    JamesNDHussainSAHallE. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med2012;366:14771488.

  • 64.

    HerrHW. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol1987;138:11621163.

  • 65.

    MakRHZietmanALHeneyNM. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int2008;102:13451353.

  • 66.

    PicozziSRicciCGaetaM. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J Urol2012;188:20462054.

    • Search Google Scholar
    • Export Citation
  • 67.

    KaufmanDRaghavanDCarducciM. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol2000;18:19211927.

    • Search Google Scholar
    • Export Citation
  • 68.

    von der MaaseHSengelovLRobertsJT. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol2005;23:46024608.

    • Search Google Scholar
    • Export Citation
  • 69.

    De SantisMBellmuntJMeadG. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II—results of EORTC study 30986. J Clin Oncol2009;27:56345639.

    • Search Google Scholar
    • Export Citation
  • 70.

    BellmuntJvon der MaaseHMeadGM. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol2012;30:11071113.

    • Search Google Scholar
    • Export Citation
  • 71.

    BurchPARichardsonRLChaSS. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol2000;164:15381542.

  • 72.

    MeluchAAGrecoFABurrisHA3rd. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol2001;19:30183024.

    • Search Google Scholar
    • Export Citation
  • 73.

    BellmuntJGuillemVPaz-AresL. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol2000;18:32473255.

    • Search Google Scholar
    • Export Citation
  • 74.

    HussainMVaishampayanUDuW. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol2001;19:25272533.

    • Search Google Scholar
    • Export Citation
  • 75.

    PectasidesDGlotsosJBountouroglouN. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol2002;13:243250.

    • Search Google Scholar
    • Export Citation
  • 76.

    LorussoVPolleraCFAntimiM. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer1998;34:12081212.

    • Search Google Scholar
    • Export Citation
  • 77.

    McCaffreyJAHiltonSMazumdarM. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol1997;15:18531857.

    • Search Google Scholar
    • Export Citation
  • 78.

    PapamichaelDGallagherCJOliverRT. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer1997;75:606607.

    • Search Google Scholar
    • Export Citation
  • 79.

    VaughnDJBroomeCMHussainM. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol2002;20:937940.

    • Search Google Scholar
    • Export Citation
  • 80.

    De SantisMBellmuntJMeadG. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol2012;30:191199.

    • Search Google Scholar
    • Export Citation
  • 81.

    BellmuntJTheodoreCDemkovT. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol2009;27:44544461.

    • Search Google Scholar
    • Export Citation
  • 82.

    GaronEBRizviNAHuiR. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med2015;372:20182028.

  • 83.

    BrahmerJReckampKLBaasP. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med2015;373:123135.

    • Search Google Scholar
    • Export Citation
  • 84.

    PostowMAChesneyJPavlickAC. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med2015;372:20062017.

  • 85.

    LarkinJChiarion-SileniVGonzalezR. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med2015;373:2334.

    • Search Google Scholar
    • Export Citation
  • 86.

    WolchokJDKlugerHCallahanMK. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med2013;369:122133.

  • 87.

    LeDTUramJNWangH. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med2015;372:25092520.

  • 88.

    AlexandrovLBNik-ZainalSWedgeDC. Signatures of mutational processes in human cancer. Nature2013;500:415421.

  • 89.

    Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature2014;507:315322.

  • 90.

    PlimackERBellmuntJGuptaS. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol2017;18:212220.

    • Search Google Scholar
    • Export Citation
  • 91.

    BellmuntJde WitRVaughnDJ. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med2017;376:10151026.

  • 92.

    O'DonnellPHGrivasPBalarAV. Biomarker findings and mature clinical results from KEYNOTE-052: first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC) [abstract]. J Clin Oncol2017;35(Suppl):Abstract 4502.

    • Search Google Scholar
    • Export Citation
  • 93.

    RosenbergJEHoffman-CensitsJPowlesT. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet2016;387:19091920.

    • Search Google Scholar
    • Export Citation
  • 94.

    BalarAVGalskyMDRosenbergJE. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet2017;389:6776.

    • Search Google Scholar
    • Export Citation
  • 95.

    Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer. Available at: http://www.roche.com/media/store/releases/med-cor-2017-05-10.htm. Accessed July 26 2017.

    • Search Google Scholar
    • Export Citation
  • 96.

    SharmaPRetzMSiefker-RadtkeA. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol2017;18:312322.

    • Search Google Scholar
    • Export Citation
  • 97.

    SharmaPBonoPKimJW. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer: results from the phase I/II CheckMate 032 study [abstract]. J Clin Oncol2016;34(Suppl):Abstract 4501.

    • Search Google Scholar
    • Export Citation
  • 98.

    MassardCGordonMSSharmaS. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol2016;34:31193125.

    • Search Google Scholar
    • Export Citation
  • 99.

    PowlesTO'DonnellPHMassardC. Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma [abstract]. J Clin Oncol2017;35(Suppl);Abstract 286.

    • Search Google Scholar
    • Export Citation
  • 100.

    ApoloABInfanteJRBalmanoukianA. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a Mmulticenter, phase Ib study. J Clin Oncol2017;35:21172124.

    • Search Google Scholar
    • Export Citation
  • 101.

    PatelMREllertonJAInfanteJR. Avelumab in patients with metastatic urothelial carcinoma: pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial [abstract]. J Clin Oncol2017;35(Suppl):Abstract 330.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 1 0
Full Text Views 3014 3011 264
PDF Downloads 772 772 79
EPUB Downloads 0 0 0